Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy
Clinical trial NCT04928261 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04928261
- Sponsor
- Ottawa Hospital Research Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-13
- Primary completion
- 2025-12-15
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.